ADAM KARNS: Open Payments
NPI 1811979198 · BEVERLY HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$10,292 in 139 payments from 27 companies in 2025. Trend: 2023 $5,029 · 2024 $4,095 · 2025 $10,292
Consulting: $5,222Food & beverage: $4,382Travel & lodging: $687
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 12 | $6,097 |
| Neurocrine BioSciences, Inc. | 24 | $910 |
| AstraZeneca Pharmaceuticals LP | 17 | $479 |
| Amgen Inc. | 5 | $352 |
| Axsome Therapeutics, Inc. | 18 | $335 |
| ABBVIE INC. | 9 | $277 |
| Gilead Sciences, Inc. | 4 | $220 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $209 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $180 |
| BridgeBio Pharma, Inc. | 1 | $167 |
Products named: Veozah, INGREZZA, Auvelity, BREZTRI, Kerendia, VRAYLAR, REPATHA, Attruby.
Industry payments across CA — which companies pay providers there.
